These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30450637)

  • 1. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
    Lyden P; Pryor KE; Coffey CS; Cudkowicz M; Conwit R; Jadhav A; Sawyer RN; Claassen J; Adeoye O; Song S; Hannon P; Rost NS; Hinduja A; Torbey M; Lee JM; Benesch C; Rippee M; Rymer M; Froehler MT; Clarke Haley E; Johnson M; Yankey J; Magee K; Qidwai J; Levy H; Mark Haacke E; Fawaz M; Davis TP; Toga AW; Griffin JH; Zlokovic BV;
    Ann Neurol; 2019 Jan; 85(1):125-136. PubMed ID: 30450637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.
    Lyden P; Weymer S; Coffey C; Cudkowicz M; Berg S; O'Brien S; Fisher M; Haley EC; Khatri P; Saver J; Levine S; Levy H; Rymer M; Wechsler L; Jadhav A; McNeil E; Waddy S; Pryor K
    Stroke; 2016 Dec; 47(12):2979-2985. PubMed ID: 27803392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to Lyden P, Pryor KE, Coffey CS, et al. Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. Ann Neurol 2019;85:125-136.
    Ann Neurol; 2024 Feb; 95(2):417. PubMed ID: 38126938
    [No Abstract]   [Full Text] [Related]  

  • 4. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
    Wang Y; Zhao Z; Chow N; Ali T; Griffin JH; Zlokovic BV
    Brain Res; 2013 Apr; 1507():97-104. PubMed ID: 23438513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
    Wang Y; Zhao Z; Chow N; Rajput PS; Griffin JH; Lyden PD; Zlokovic BV
    Stroke; 2013 Dec; 44(12):3529-36. PubMed ID: 24159062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.
    Williams PD; Zlokovic BV; Griffin JH; Pryor KE; Davis TP
    Curr Pharm Des; 2012; 18(27):4215-22. PubMed ID: 22632606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Thrombus Length on Outcomes After Intra-Arterial Aspiration Thrombectomy in the THERAPY Trial.
    Yoo AJ; Khatri P; Mocco J; Zaidat OO; Gupta R; Frei D; Lopes D; Shownkeen H; Berkhemer OA; Meyer D; Hak SS; Kuo SS; Buell H; Bose A; Sit SP; von Kummer R;
    Stroke; 2017 Jul; 48(7):1895-1900. PubMed ID: 28596447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.
    Lyden P; Levy H; Weymer S; Pryor K; Kramer W; Griffin JH; Davis TP; Zlokovic B
    Curr Pharm Des; 2013; 19(42):7479-85. PubMed ID: 24372304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
    Wang Y; Zhang Z; Chow N; Davis TP; Griffin JH; Chopp M; Zlokovic BV
    Stroke; 2012 Sep; 43(9):2444-9. PubMed ID: 22811462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.
    Pancioli AM; Adeoye O; Schmit PA; Khoury J; Levine SR; Tomsick TA; Sucharew H; Brooks CE; Crocco TJ; Gutmann L; Hemmen TM; Kasner SE; Kleindorfer D; Knight WA; Martini S; McKinney JS; Meurer WJ; Meyer BC; Schneider A; Scott PA; Starkman S; Warach S; Broderick JP;
    Stroke; 2013 Sep; 44(9):2381-7. PubMed ID: 23887841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone.
    Mocco J; Zaidat OO; von Kummer R; Yoo AJ; Gupta R; Lopes D; Frei D; Shownkeen H; Budzik R; Ajani ZA; Grossman A; Altschul D; McDougall C; Blake L; Fitzsimmons BF; Yavagal D; Terry J; Farkas J; Lee SK; Baxter B; Wiesmann M; Knauth M; Heck D; Hussain S; Chiu D; Alexander MJ; Malisch T; Kirmani J; Miskolczi L; Khatri P;
    Stroke; 2016 Sep; 47(9):2331-8. PubMed ID: 27486173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.
    Bracard S; Ducrocq X; Mas JL; Soudant M; Oppenheim C; Moulin T; Guillemin F;
    Lancet Neurol; 2016 Oct; 15(11):1138-47. PubMed ID: 27567239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial.
    Renú A; Millán M; San Román L; Blasco J; Martí-Fàbregas J; Terceño M; Amaro S; Serena J; Urra X; Laredo C; Barranco R; Camps-Renom P; Zarco F; Oleaga L; Cardona P; Castaño C; Macho J; Cuadrado-Godía E; Vivas E; López-Rueda A; Guimaraens L; Ramos-Pachón A; Roquer J; Muchada M; Tomasello A; Dávalos A; Torres F; Chamorro Á;
    JAMA; 2022 Mar; 327(9):826-835. PubMed ID: 35143603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
    Luby M; Hsia AW; Nadareishvili Z; Cullison K; Pednekar N; Adil MM; Latour LL
    Stroke; 2019 Aug; 50(8):2241-2244. PubMed ID: 31238832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Intravenous Thrombolysis and Thrombectomy vs Thrombectomy Alone for Acute Ischemic Stroke: A Pooled Analysis of the SWIFT and STAR Studies.
    Coutinho JM; Liebeskind DS; Slater LA; Nogueira RG; Clark W; Dávalos A; Bonafé A; Jahan R; Fischer U; Gralla J; Saver JL; Pereira VM
    JAMA Neurol; 2017 Mar; 74(3):268-274. PubMed ID: 28097310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial.
    Suzuki K; Matsumaru Y; Takeuchi M; Morimoto M; Kanazawa R; Takayama Y; Kamiya Y; Shigeta K; Okubo S; Hayakawa M; Ishii N; Koguchi Y; Takigawa T; Inoue M; Naito H; Ota T; Hirano T; Kato N; Ueda T; Iguchi Y; Akaji K; Tsuruta W; Miki K; Fujimoto S; Higashida T; Iwasaki M; Aoki J; Nishiyama Y; Otsuka T; Kimura K;
    JAMA; 2021 Jan; 325(3):244-253. PubMed ID: 33464334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Receiving Thrombectomy: Standard or Low Dose Therapy?
    Lin CH; Liu CH; Wang AY; Wu YM; Chen CC; Tsai YH; Chang TY; Huang KL; Wu HC; Lee TH; Chang YJ; Lin CM; Cheng CK; Chang CH
    Curr Neurovasc Res; 2018; 15(3):204-210. PubMed ID: 30014803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
    Barreto AD; Ford GA; Shen L; Pedroza C; Tyson J; Cai C; Rahbar MH; Grotta JC;
    Stroke; 2017 Jun; 48(6):1608-1616. PubMed ID: 28507269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
    Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
    Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial.
    Pérez de la Ossa N; Abilleira S; Jovin TG; García-Tornel Á; Jimenez X; Urra X; Cardona P; Cocho D; Purroy F; Serena J; San Román Manzanera L; Vivanco-Hidalgo RM; Salvat-Plana M; Chamorro A; Gallofré M; Molina CA; Cobo E; Davalos A; Ribo M;
    JAMA; 2022 May; 327(18):1782-1794. PubMed ID: 35510397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.